An estimated six million people worldwide are living with Parkinson’s disease.
There remains no cure for this devastating neurodegenerative condition. However, over the last decade, 23andMe researchers and our collaborators have made important strides. We now have a better understanding of the causes and progression of the disease.
Now 23andMe’s Parkinson’s Research Community is by far the largest cohort of its kind. Participants in this research, are both re-contactable and deeply phenotyped. It has become an enormous resource for Parkinson’s research.
Powering Parkinson’s Research with My Blueprint
Claudia shares her perspective on living with Parkinson's and on why she participates in Parkinson's research in this post that first appeared on the Michael J. Fox Foundation blog.
Read More
Participating in 23andMe Research, A Customer’s Perspective
23andMe research participant Tony Garrett gives his perspective on why he is participating in research and his hopes for the future.
Read More
New Parkinson’s Disease Research May Offer Promise for Early Detection
New Parkinson’s disease research by scientists at 23andMe has identified more than 100 phenotypic variables related to the disease, offering a potential step forward in efforts to diagnose Parkinson’s disease...
Read More
October Insights into Parkinson’s Research
An update on recruitment for the Fox Insights Parkinson's research initiative.
Read More
An Interview with 23andMe’s Parkinson’s disease program Manager Paul Cannon
23andMe's Parkinson's research community manager, Paul Cannon shares his experience with Deep Brain Stimulation to treat his Parkinson's symptoms.
Read More
New Parkinson’s Disease Research Collaboration with the Michael J. Fox Foundation
As part of a broad collaboration with the Michael J. Fox Foundation, 23andMe is inviting participants in its Parkinson's Research community to participate in a new initiative called Fox Insights to make data broadly available to qualified researchers worldwide starting in 2018, with the goals of sparking innovation and discoveries around Parkinson’s disease.
Read More
Update on 23andMe Parkinson’s disease research
Participants in the 23andMe Parkinson’s disease research initiative have contributed a vast amount of data, that has enabled our researchers and collaborators to improve our understanding of the genetics of...
Read More
New Genetic Associations for Parkinson’s Disease Identified
Scientists at 23andMe and Genentech have identified 17 new genetic variants associated with Parkinson’s disease, almost doubling the total number of known risk variants for the condition, which gives scientists hints at potential new targets for drugs to treat the disease.
Read More
Learn More About 23andMe’s New Genetic Health Risk Reports
23andMe recently started offering customers new Genetic Health Risk reports that have received FDA authorization. Below we’ve highlighted some important features in these reports to help you get more out...
Read More
Parkinson’s Awareness Month
April is Parkinson’s Awareness Month and this year it also marks the eighth anniversary of 23andMe’s Parkinson’s Research Community, which introduced a game-changing model for science, one that leverages online...
Read More